Xeris Pharmaceuti…
USUSDXeris Pharmaceuticals Inc (LSE:0A8E) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- xerispharma.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- CHICAGO, United States
- Management
- John P. Shannon
- Mitarbeiter
- 435
- Börsennotiert Seit
- 14.10.2021 (LSE:0A8E)
- Ausstehende Aktien
- 182.32 Mio. Stand 2026-07-31
- Streubesitz
- 176.07 Mio.
- Marktkapitalisierung
- 1.91 Mrd. USD
- Insider
- 3.03%
- Institutionelle Anleger
- 60.12%
- Branche (SIC)
- Pharmaceutical Preparations
- P/E
- Verlust
- FCF
- 55.7 Mio. USD
- Schulden
- 253 Mio. USD2.4 J. FCF
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- Nettogewinn
- NAV
Beschreibung
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 7.97% | 14.53 Mio. | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 4.28% | 7.8 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.03% | 7.34 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.85% | 5.19 Mio. | 2026-06-30 |
| State Street Corporation | 2.64% | 4.82 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.59% | 4.72 Mio. | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.41% | 4.39 Mio. | 2026-08-31 |
| Nuveen, LLC | 2.41% | 4.39 Mio. | 2026-06-30 |
| SHANNON JOHN PATRICK JR… | ≈1.61% | 2.94 Mio. | 2026-01-30 |
| Rosalind Advisors, Inc. | 1.6% | 2.91 Mio. | 2026-06-30 |
| Qube Research & Technolo… | 1.59% | 2.89 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 1.44% | 2.63 Mio. | 2026-06-30 |
| Wellington Management Gr… | 1.3% | 2.37 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.09% | 1.99 Mio. | 2026-06-30 |
| College Retirement Equit… | 1.07% | 1.95 Mio. | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.02% | 1.87 Mio. | 2026-07-31 |
| MCCULLOCH KEVIN (Preside… | ≈0.9% | 1.64 Mio. | 2026-09-28 |
| iShares Trust-iShares Ru… | 0.87% | 1.59 Mio. | 2026-08-31 |
| PIEPER STEVEN (Chief Fin… | ≈0.74% | 1.36 Mio. | 2026-09-01 |
| TIAA-CREF Funds-Nuveen Q… | 0.66% | 1.2 Mio. | 2026-07-31 |
| HECHT BETH P (Officer) | ≈0.62% | 1.13 Mio. | 2026-09-01 |
| SPDR SERIES TRUST-State… | 0.56% | 1.03 Mio. | 2026-08-31 |
| First TRT Exch-Trd Alpha… | 0.53% | 959 282 | 2026-08-31 |
| Fidelity Covington Trust… | 0.5% | 919 795 | 2026-09-30 |
| Fidelity Concord Street… | 0.48% | 868 756 | 2026-07-31 |
| JOHNSON JOHN H. (Directo… | ≈0.38% | 698 083 | 2025-12-19 |
| NGUYEN ANH TU (Officer) | ≈0.24% | 431 534 | 2026-01-30 |
| KONG GARHENG (Director) | ≈0.13% | 238 337 | 2026-06-04 |
| SHERMAN JEFFREY W (Direc… | ≈0.12% | 224 588 | 2025-08-28 |
| PERSKY MARLA S (Director… | ≈0.09% | 157 063 | 2026-06-04 |
| BORMANN-KENNEDY BARBARA-… | ≈0.08% | 150 693 | 2026-06-04 |
Mit Google Anmelden